Geneva Biotech 带有感受态细胞的完整SynBac试剂盒

 传统的使用杆状病毒扩大生产过程是出了名的问题，在扩大生产过程中产量逐渐下降。synbac™是利用现代合成生物学技术创造的最小化杆状病毒基因组。Synbac项目的目标是改造发酵罐规模的杆状病毒生产的药物目标，并制造规模生产的生物制药通过创造最小的杆状病毒基因组显示卓越的DNA稳定性。除了提高DNA稳定性外，我们最小化的基因组也成为了应用的起点，需要向哺乳动物细胞、原代细胞或器官输送大量DNA。

Traditional process scale up using baculovirus is notoriously problematic, with yields dropping progressively during scale up. SynBac™ are minimized baculoviral genomes created using modern synthetic biology techniques. The SynBac project aims to transform fermenter-scale baculoviral production of drug targets, and manufacturing scale production of biopharmaceuticals by creating minimal baculoviral genomes displaying exceptional DNA stability. In addition to improved DNA stability, our minimized genomes form the starting point for applicaions that require large DNA cargo delivery to mammalian cells, primary cells, or organs.

EMBL和ISTL进行了比较基因组分析和密集的数据挖掘，以确定杆状病毒基因组中对DNA稳定性有潜在危害的区域，或者不重要的区域，可以丢弃或重新设计（见下图）。目前，大量的acmnpv基因组片段正在重新布线，并测试关键参数，如表达量和DNA稳定性。在一个迭代过程中，改进的基因组被用作进一步的基因组最小化和优化的模板。

EMBL and IStLS carried out a comparative genome analysis and intense data mining to identify regions of the baculovirus genome that are potentially harmful for DNA stability, or are otherwise non-essential and can be discarded or re-engineering (see circle map below). Large sections of the AcMNPV genome are presently being rewired and tested for critical parameters such as expression yield and DNA stability. In an iterative process, improved genomes are being used as templates for further rounds of genome minimization and optimization.

下面是acmnpv基因组（圆图）的示意图。为了提供一个例子，synbac1.0基因组的重组目标用阴影三角形表示。

Below is a schematic representation of the AcMNPV genome (circle map). To provide an example, the rewiring target of the SynBac1.0 genome is indicated by the shaded triangle.

Kits